AU · rank #20 · 2026-09-11
DSFIR
AMSTERDAM · EUR · $25.65B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.650 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.04 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 13 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $93.62 | +4.0% |
| Momentum acceleration 3-month minus 12-month momentum. | +18.07% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.05 |
| Gross margin TTM | +39.2% |
| 52w high | $96.74 |
| Market cap (USD) | $25.65B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
DSM-Firmenich is a global specialty ingredients and fragrance group serving consumer, food, pet and healthcare markets through proprietary taste, nutrition and beauty platforms.
Rationale
Universal 30-day EPS revision agreement (100% of 19 analysts revising up), accelerating Q2 EBITDA momentum (+10% LFL, ~3% consensus beat) and management guiding to the upper end of full-year targets collectively validate the analyst_upside signal as grounded in fundamental earnings inflection rather than mere sentiment rotation.
Material risks
- 1Synthetic biology and digital formulation advances could commoditize fragrance aroma chemicals and bio-active nutrition ingredients, directly eroding the proprietary technology moat that justifies premium pricing and analyst target upgrades.
- 2Large consumer and food customers insourcing formulation capability or switching to lower-cost ingredient suppliers would compress DSM-Firmenich's share of wallet and undercut the volume-growth trajectory that underpins current upward EPS revisions.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.